Liver fibrosis
-
Resmetirom: A New FDA-approved Drug as a Targeted Therapeutic Strategy in Metabolic Dysfunction Associated Steatohepatitis: Translational Evidence from Current Clinical Trials
Ghulam Hassam-u-din Tarrar, Syed Shafaat Hussain, Muhammad Raza Sarfraz, Malka A. Hassan, Tushar Kanti Bhadra
2026, Vol. 127, Issue 3, pp. 145-150
